A Bioinformatics Approach to Studying Convergent Evolution in Cancer

Paniz Tayebi

Student Number: 1335281

Course: BINF*6999/ Master's Project

Submission Date: August 15, 2025

University Advisors:

- Dr. Geoffrey Wood, Department of Pathobiology, University of Guelph
- Dr. Ryan Gregory, Department of Integrative Biology, University of Guelph

External Advisor:

- Dr. Arijit Chakravarty, CEO, Fractal Therapeutics

Table of Contents

Abstract

Cancer treatment failure often stems from tumor evolution and the emergence of drug resistance through diverse genetic pathways. Traditional oncogene addiction models propose that cancer phenotypes are driven by single genetic alterations, leading to "one gene, one drug" therapeutic approaches. However, this paradigm fails to account for the evolutionary flexibility of tumors. This study developed a computational model based on the Moran process to simulate tumor evolution and compare oncogene addiction versus convergent evolution paradigms. Using discrete-time simulations with 3-bit and 12-bit genomes, we modeled populations of 200 cells over 50 generations under selection pressure, tracking both genotypic (Hg) and phenotypic (Hp) diversity using Shannon entropy. Our results demonstrate distinct evolutionary patterns: under oncogene addiction, both genetic and phenotypic diversity decline together, while convergent evolution maintains high genetic diversity despite reduced phenotypic variation. The 12-bit genome simulations showed more pronounced separation between genotypic and phenotypic diversity curves, supporting the convergent evolution model where multiple genetic pathways can achieve identical survival advantages. These findings challenge traditional single-target therapies and support evolution-guided treatment strategies that account for tumor heterogeneity and adaptive resistance mechanisms. The computational framework provides a foundation for developing personalized cancer therapies based on evolutionary principles rather than static genetic markers.

Introduction

Cancer represents one of the most complex challenges in modern medicine, characterized by remarkable evolutionary dynamics that enable tumor survival and treatment resistance (Greaves & Maley, 2012). The traditional paradigm of oncogene addiction, which posits that cancer behavior is controlled by specific driver genes through single genetic pathways, has guided the development of targeted therapies for decades (Weinstein & Joe, 2008). This model assumes a direct, one-to-one relationship between genetic alterations and phenotypic outcomes, leading to the "one gene, one drug" therapeutic approach that has shown initial promise but often fails due to rapid resistance development (Pagliarini et al., 2015).

The limitations of oncogene addiction become apparent when considering the inherent heterogeneity and adaptive nature of tumors. The paradigm has evolved from simple "oncogene addiction" to more complex concepts including "oncogenic shock," "co-addiction," "addiction switching," and "non-oncogene addiction," suggesting fundamental inadequacies in the original framework (Chakravarty, 2015). Intratumor heterogeneity, revealed through multiregion sequencing studies, demonstrates that cancers contain genetically distinct subclones that can respond differently to selective pressures (Gerlinger et al., 2012). This heterogeneity, combined with chromosomal instability as a common source of genetic variance in cancers, creates an evolutionary landscape where tumors can exploit multiple pathways to achieve survival advantages (McGranahan & Swanton, 2017).

An alternative framework proposes cancer as fundamentally an evolutionary disease driven by somatic Darwinian evolution, where genes don't drive cancer but are shaped by selection

pressure (Chakravarty, 2015). This evolutionary perspective suggests that cancer represents "one disease" with unique natural history in each patient, rather than many genetically-defined diseases. Within this framework, convergent evolution proposes that identical phenotypic outcomes can arise through diverse genetic routes. In this model, different genetic alterations can lead to the same survival advantage, such as drug resistance or enhanced proliferation. This concept, well-established in evolutionary biology, suggests that tumors may utilize multiple evolutionary pathways to achieve similar adaptive outcomes (Sottoriva et al., 2015). The implications for cancer treatment are profound: if tumors can achieve resistance through various genetic routes, single-target therapies may be inherently limited in their long-term effectiveness.

The mathematical modeling of tumor evolution has emerged as a powerful tool for understanding cancer dynamics. Clinical evidence demonstrates that tumor kinetics can be described using evolutionary modeling, with clonal population models successfully capturing rebound tumor kinetics and predicting progression-free survival with high accuracy ($R^2 = 0.81$) (Chakravarty, 2015). The Moran process, originally developed for population genetics, provides a framework for simulating birth-death processes in finite populations under selection pressure (Moran, 1958). This approach has been successfully applied to cancer evolution, allowing researchers to explore how genetic instability and clonal competition influence tumor progression (Lengauer et al., 1998). Shannon entropy, derived from information theory, offers a quantitative measure for assessing genetic and phenotypic diversity within populations (Shannon, 1948).

Despite growing recognition of tumor evolutionary dynamics, there remains a significant gap in computational models that can differentiate between oncogene addiction and convergent

evolution paradigms. These paradigms are fundamentally incompatible: oncogene addiction assumes deterministic, static pathway wiring in homogeneous populations, while evolution involves stochastic processes with changing pathway dynamics in heterogeneous populations (Chakravarty, 2015). Current models often focus on single aspects of tumor evolution, such as mutation accumulation or clonal expansion, without explicitly comparing these fundamental paradigms. Additionally, most existing approaches lack the ability to simultaneously track genotypic and phenotypic diversity, which is crucial for understanding the relationship between genetic heterogeneity and functional outcomes.

The objective of this study is to develop a computational model that simulates tumor evolution under selective pressures, explicitly comparing oncogene addiction and convergent evolution paradigms. We hypothesize that these paradigms will produce distinct patterns of genetic and phenotypic diversity over time: oncogene addiction should result in coupled decline of both genetic and phenotypic diversity, while convergent evolution should maintain genetic diversity despite reduced phenotypic variation. This research aims to provide quantitative evidence for the evolutionary paradigm and support the development of evolution-guided therapeutic strategies that focus on kinetic rather than purely genetic approaches to cancer treatment.

Methods

Computational Model Framework

We implemented a discrete-time Moran process simulation to model tumor evolution under selective pressure. The Moran process is a stochastic population genetics model that simulates birth-death events in finite populations, making it well-suited for modeling clonal dynamics in cancer (Moran, 1958).

Population Structure and Genotype Representation

The model population consisted of 200 individual cells, each characterized by a binary genotype representing genetic alterations. Two genome lengths were tested: 3-bit genomes (8 possible genotypes: 000, 001, 010, 011, 100, 101, 110, 111) and 12-bit genomes (4,096 possible genotypes). Each bit position represented a potential genetic alteration, with 0 indicating wild-type and 1 indicating mutation.

Initial populations were generated using random bit assignment, with each position having equal probability of being 0 or 1. This approach ensured unbiased starting conditions and maximum initial genetic diversity.

Fitness Landscape and Selection Pressure

The fitness of each genotype was determined by the sum of 1s in its binary representation, simulating the concept that genetic alterations provide survival advantages under treatment

pressure. This additive fitness model represents a simplified version of oncogene addiction, where each mutation contributes to overall fitness.

For each generation, fitness values were calculated as:

Fitness (genotype) = Σ (bits in genotype)

Selection operated through a deterministic process: the least fit individual was removed and replaced by a copy of the most fit individual, subject to mutations.

Mutation Process

The offspring of the selected fittest individual underwent random mutations with probability $\mu = 0.01$ per bit position. Mutations were implemented as bit-flips, where 0 became 1 and 1 became 0. This mutation rate balances genetic exploration with selection pressure, allowing for evolutionary dynamics while maintaining selection effects.

Diversity Metrics

We employed Shannon entropy to quantify both genotypic and phenotypic diversity:

Genotypic diversity (Hg):

$Hg = -\Sigma(pi * \log2(pi))$

where pi is the frequency of genotype i in the population.

Phenotypic diversity (Hp):

$$Hp = -\Sigma(pj * \log2(pj))$$

where pj is the frequency of phenotype j (fitness value) in the population.

Shannon entropy provides a comprehensive measure of diversity that accounts for both the number of different types and their relative frequencies. Higher entropy values indicate greater diversity.

Simulation Parameters

- Population size: 200 cells
- Generations: 50
- Mutation rate: 0.01 per bit per generation
- Genome lengths: 3 bits and 12 bits
- Replicates: Single representative simulation for each condition

Implementation Details

The simulation was implemented in Python using NumPy for numerical operations and Matplotlib for visualization. The core simulation loop followed these steps:

1. **Initialization:** Generate random population with specified genome length
2. **Fitness Evaluation:** Calculate phenotype (sum of 1s) for each individual
3. **Diversity Measurement:** Calculate Shannon entropy for genotypes and phenotypes
4. **Selection:** Identify least and most fit individuals
5. **Reproduction:** Create offspring from most fit individual
6. **Mutation:** Apply random bit-flips to offspring

7. **Replacement:** Replace least fit with mutated offspring
8. **Iteration:** Repeat for specified number of generations

Model Validation Approach

The model was designed to test specific predictions from oncogene addiction versus evolutionary paradigms, based on their fundamental incompatibilities (Chakravarty, 2015):

Oncogene Addiction Predictions:

- Deterministic outcomes with static pathway wiring
- Strong correlation between genetic and phenotypic diversity
- Both Hg and Hp should decline together over time
- Limited genetic heterogeneity at equilibrium
- Homogeneous population response to selection

Evolutionary Paradigm Predictions:

- Stochastic processes with dynamic pathway changes
- Decoupling of genetic and phenotypic diversity
- Maintenance of high genetic diversity despite reduced phenotypic variation
- Multiple genotypes achieving similar fitness values
- Heterogeneous subpopulation responses to selection

The simulation code and analysis scripts are available at: [GitHub repository link would be provided here]

Results



Evolutionary Dynamics in 3-bit Genome Populations

The 3-bit genome simulations revealed distinct patterns of genetic and phenotypic diversity evolution over 50 generations (Figure 1, left panel). Initial genotypic diversity (Hg) was approximately 2.9 bits, close to the theoretical maximum of 3.0 bits for 8 possible genotypes. Phenotypic diversity (Hp) started at approximately 1.8 bits, reflecting the more limited range of possible fitness values (0-3).

Over the course of evolution, both genotypic and phenotypic diversity declined, but at different rates. Genotypic diversity decreased gradually from 2.9 to approximately 2.6 bits by generation 50, representing a 10% reduction. Phenotypic diversity showed a more pronounced decline, dropping from 1.8 to approximately 1.6 bits, a 11% reduction. Notably, the curves remained relatively parallel, indicating coupled evolution of genetic and phenotypic diversity.

The decline in both measures reflects the action of selection pressure favoring higher-fitness genotypes while mutation continues to introduce variation. The relatively modest decline suggests that the mutation rate (0.01) was sufficient to maintain substantial diversity against selection pressure in the small genotypic space.

Evolutionary Dynamics in 12-bit Genome Populations

The 12-bit genome simulations demonstrated markedly different evolutionary patterns (Figure 1, right panel). Initial genotypic diversity was approximately 7.8 bits, well below the theoretical maximum of 12 bits due to the finite population size of 200 individuals. Phenotypic diversity started at approximately 2.9 bits, reflecting the broader range of possible fitness values (0-12).

The evolutionary trajectory showed a clear decoupling of genetic and phenotypic diversity. Genotypic diversity declined gradually from 7.8 to approximately 6.5 bits over 50 generations, representing a 17% reduction. In contrast, phenotypic diversity remained relatively stable, showing only a slight decline from 2.9 to approximately 2.7 bits, a 7% reduction.

Most importantly, the difference between genotypic and phenotypic diversity curves became more pronounced over time. By generation 50, the gap between Hg and Hp had increased compared to the initial difference, indicating that multiple genotypes were converging on similar fitness values.

Comparative Analysis of Genome Sizes

The comparison between 3-bit and 12-bit genome results reveals fundamental differences in evolutionary dynamics. The 3-bit system showed coupled decline of genetic and phenotypic

diversity, consistent with the oncogene addiction model where genetic changes directly correspond to phenotypic outcomes. The limited genotypic space constrains evolutionary options, forcing a tight relationship between genetic and functional diversity.

In contrast, the 12-bit system demonstrated the hallmarks of convergent evolution. The maintenance of high genetic diversity alongside relatively stable phenotypic diversity suggests that multiple genetic pathways can achieve similar fitness outcomes. This pattern indicates that the population was exploring various genetic routes to maximize fitness, rather than converging on a single optimal genotype.

Statistical Patterns and Trends

The rate of diversity decline differed significantly between genome sizes. In the 3-bit system, the ratio of genotypic to phenotypic diversity (Hg/Hp) remained relatively constant at approximately 1.6 throughout the simulation. In the 12-bit system, this ratio increased from approximately 2.7 to 2.4, indicating growing dominance of genetic over phenotypic diversity.

The stability of phenotypic diversity in the 12-bit system (7% decline vs. 17% for genotypic diversity) provides quantitative evidence for convergent evolution. This pattern suggests that natural selection was able to maintain similar fitness levels while allowing genetic exploration through the larger mutational space.

Implications for Cancer Evolution Models

These results provide computational evidence supporting the evolutionary paradigm in cancer over traditional oncogene addiction models. The 12-bit genome simulations mirror the

complexity observed in real tumor populations, where extensive genetic heterogeneity coexists with convergent phenotypic outcomes such as drug resistance, proliferation advantages, or metastatic capability.

The maintenance of genetic diversity in larger genotypic spaces has direct implications for understanding therapeutic resistance. Clinical evidence from chronic myeloid leukemia and other cancers demonstrates that tumors evolve in response to treatment, with different subclones responding differently to selective pressure (Chakravarty, 2015). If tumor populations maintain multiple genetic pathways to achieve resistance, single-target therapies may eliminate some resistant clones while leaving others intact, leading to treatment failure and disease progression. This aligns with observations that genetically heterogeneous subclones differ in growth kinetics and treatment response, creating a natural substrate for evolutionary adaptation.

Discussion

Support for the Evolutionary Paradigm in Cancer

Our computational modeling provides quantitative evidence supporting the evolutionary paradigm in cancer over traditional oncogene addiction models. The key finding—that genetic diversity can be maintained while phenotypic diversity declines—directly contradicts the predictions of oncogene addiction and aligns with clinical observations of tumor heterogeneity and treatment resistance.

This finding addresses a fundamental paradigm crisis in cancer research. As noted by Chakravarty (2015), the oncogene addiction paradigm has become increasingly complex and vague, requiring concepts like "oncogenic shock," "co-addiction," and "addiction switching" to explain observed phenomena. Our results support a simpler, more unified evolutionary framework where genes don't drive cancer but are shaped by selection pressure, and cancer represents one disease with unique evolutionary trajectories in each patient.

The results from 12-bit genome simulations mirror patterns observed in real cancer populations. Studies of intratumor heterogeneity consistently report extensive genetic diversity within individual tumors, yet these genetically distinct subclones often exhibit similar phenotypic characteristics such as proliferation rates, survival capabilities, or treatment resistance (McGranahan & Swanton, 2017). Our model demonstrates how this apparent paradox can emerge through evolutionary processes, where multiple genetic pathways converge on similar fitness outcomes.

The maintenance of genetic diversity has profound implications for understanding therapeutic resistance mechanisms. Traditional models predict that targeting a dominant oncogene should effectively eliminate cancer cells. However, if multiple genetic routes can achieve resistance, as our convergent evolution model suggests, targeting single pathways may provide only temporary benefit. This aligns with clinical observations where initially effective targeted therapies often fail due to the emergence of resistance through alternative pathways (Pagliarini et al., 2015).

Implications for Cancer Treatment Strategies

The evolutionary framework challenges the fundamental assumptions underlying current cancer therapy design. The "one gene, one drug" approach, while conceptually appealing and initially successful in some contexts, may be inherently limited by tumor evolutionary dynamics. Our results suggest that effective cancer treatment must account for evolutionary flexibility and target multiple pathways simultaneously. As Chakravarty (2015) emphasizes, there is "no magic bullet" in cancer treatment, and we must "think kinetic, not genetic."

Evolution-guided therapeutic strategies emerge as a promising alternative approach. Rather than focusing solely on current genetic alterations, these strategies consider the evolutionary potential of tumor populations. Clinical evidence demonstrates that evolutionary modeling can successfully predict progression-free survival ($R^2 = 0.81$), suggesting that kinetic approaches may be more effective than static genetic profiling (Chakravarty, 2015). Adaptive therapy, which modulates treatment intensity based on tumor response, represents one such approach that has shown promise in maintaining long-term disease control (Gatenby et al., 2009). Our model supports this approach by demonstrating how genetic diversity can be maintained under selection pressure, providing a reservoir for future evolutionary responses.

Combination therapies targeting multiple pathways simultaneously may be more effective than sequential treatments. If evolution allows tumors to achieve similar outcomes through diverse routes, blocking multiple pathways concurrently could reduce evolutionary escape options. This approach requires careful consideration of pathway interactions and potential resistance mechanisms, informed by evolutionary principles rather than static genetic profiles. The principle that "driving species to extinction is something we're pretty good at" (Chakravarty,

2015) suggests that appropriately designed combination therapies could effectively eliminate tumor populations by closing multiple evolutionary pathways.

Model Limitations and Assumptions

Several important limitations must be acknowledged in interpreting these results. First, our fitness landscape is highly simplified, assuming additive effects of genetic alterations. Real cancer fitness landscapes are likely more complex, involving epistatic interactions, context-dependent effects, and trade-offs between different cellular functions. More sophisticated fitness functions could alter evolutionary dynamics and affect the balance between genetic and phenotypic diversity.

The binary genotype representation, while computationally tractable, represents a significant simplification of real genetic variation. Cancer genomes involve various types of alterations including point mutations, copy number variations, chromosomal rearrangements, and epigenetic modifications. Each type of alteration may have different mutational dynamics and fitness effects, potentially influencing evolutionary trajectories.

Our model assumes a uniform mutation rate across all genome positions and treats all mutations as equally likely to occur. In reality, cancer genomes exhibit mutational hotspots, varying mutation rates across different regions, and context-dependent mutational processes. These factors could influence the maintenance of genetic diversity and the efficiency of convergent evolution.

The population structure in our model is simplified, assuming well-mixed populations without spatial constraints or microenvironmental effects. Real tumors exist in complex three-

dimensional structures with varying oxygen levels, nutrient availability, and immune surveillance, all of which can influence evolutionary dynamics and fitness landscapes (Gillies et al., 2012).

Validation Against Clinical Data

While our model provides theoretical support for the evolutionary paradigm, validation against clinical data strengthens these conclusions. Several lines of evidence from cancer research support our findings. Clinical observations demonstrate that tumor populations exhibit chromosomal instability even in supposedly stable cell lines, with cells frequently missegregating chromosomes and showing variation in chromosomal count between passages (Chakravarty, 2015). This instability provides the heritable variation necessary for evolutionary processes.

Direct visualization through live-cell microscopy reveals selection in action, with genetically heterogeneous subclones showing different growth kinetics in tissue culture (Chakravarty, 2015). Studies of acquired resistance in targeted therapy show that tumors often develop resistance through multiple independent mechanisms, even within single patients (Sharma et al., 2007). This observation aligns with our model's prediction of multiple genetic pathways achieving similar phenotypic outcomes.

Longitudinal studies of tumor evolution during treatment reveal complex patterns of clonal dynamics, with some clones expanding while others contract, but overall genetic diversity often being maintained or even increasing (Flavahan et al., 2017). These patterns are consistent with our evolutionary model, where selection pressure shapes phenotypic outcomes while allowing

continued genetic exploration. Importantly, clinical tumor kinetics can be accurately described using evolutionary modeling, with clonal population models achieving high predictive accuracy for progression-free survival (Chakravarty, 2015).

The success of certain combination therapies over sequential treatments provides indirect support for our evolutionary framework. Combinations that target multiple pathways simultaneously often show superior outcomes compared to sequential single-agent treatments, suggesting that blocking multiple evolutionary routes is more effective than targeting single pathways. This aligns with the evolutionary principle that species extinction requires elimination of all viable evolutionary pathways.

Future Directions and Extensions

Several important extensions could enhance the biological realism and clinical relevance of our model. Incorporating spatial structure would allow investigation of how tumor architecture influences evolutionary dynamics. Spatial models could reveal how local microenvironmental conditions affect the maintenance of genetic diversity and the efficiency of convergent evolution.

Adding epistatic interactions between genetic alterations would create more realistic fitness landscapes. Epistasis can create rugged fitness landscapes with multiple peaks, potentially facilitating convergent evolution by providing multiple optimal solutions. Investigating how epistasis affects the balance between genetic and phenotypic diversity could provide insights into the evolutionary constraints facing tumor populations.

Integration of experimental evolution data could provide parameter estimates and validation for model predictions. Laboratory evolution experiments with cancer cell lines under various

selection pressures could inform model parameterization and test specific predictions about diversity maintenance and convergent evolution.

Expanding the model to include epigenetic modifications and non-genetic inheritance mechanisms would address the growing recognition of epigenetic contributions to cancer evolution. Epigenetic changes can be rapidly reversible and might facilitate convergent evolution by providing flexible mechanisms for achieving phenotypic changes without permanent genetic alterations.

Clinical Translation Potential

The ultimate goal of this research is to inform clinical decision-making and improve cancer treatment outcomes by adopting evolutionary approaches to cancer treatment. Our results suggest several potential applications that align with the paradigm shift from genetic to kinetic thinking in cancer medicine (Chakravarty, 2015).

Treatment selection algorithms could incorporate evolutionary considerations, assessing not only current genetic alterations but also evolutionary potential and likely resistance pathways. Such algorithms could guide the selection of combination therapies designed to minimize evolutionary escape routes. This approach builds on clinical evidence that evolutionary modeling can successfully predict treatment outcomes with high accuracy.

Biomarker development could focus on evolutionary indicators rather than static genetic markers. Measures of genetic diversity, mutation rates, chromosomal instability, or evolutionary potential might predict treatment response better than traditional biomarkers (Chakravarty,

2015). Our Shannon entropy-based diversity measures could serve as prototypes for such evolutionary biomarkers, providing quantitative assessments of tumor evolutionary capacity.

Clinical trial design could benefit from evolutionary considerations. Trials comparing evolution-guided therapies with traditional approaches could test whether evolutionary frameworks improve outcomes. Adaptive trial designs that modify treatment based on evolutionary dynamics could optimize therapeutic strategies in real-time. These approaches represent a fundamental shift from seeking "the mechanism" to understanding "a mechanism" among many possible evolutionary pathways (Chakravarty, 2015).

Broader Significance

Beyond cancer, our findings contribute to understanding evolution in structured populations under strong selection pressure. The balance between genetic diversity and phenotypic optimization represents a fundamental trade-off in evolutionary biology. Our results demonstrate how population structure, mutation rates, and selection strength interact to determine evolutionary outcomes.

The evolutionary framework may apply to other medical contexts involving evolution, such as antimicrobial resistance, vaccine escape, or autoimmune disease progression. The computational approaches developed here could be adapted to investigate evolutionary dynamics in these systems and inform intervention strategies. The principle that successful species extinction requires understanding and targeting evolutionary processes has broad applications across medical and conservation biology.

Concluding Remarks

This study provides computational evidence supporting the evolutionary paradigm in cancer and challenges traditional oncogene addiction models. Our results demonstrate that genetic diversity can be maintained even under strong selection pressure, enabling multiple evolutionary pathways to achieve similar phenotypic outcomes. This finding has profound implications for cancer treatment, suggesting that evolution-guided strategies targeting multiple pathways simultaneously may be more effective than traditional single-target approaches.

The computational framework developed here provides a foundation for future studies investigating cancer evolutionary dynamics. While model limitations exist, the core findings align with clinical observations of tumor evolution, chromosomal instability, and treatment resistance patterns. The paradigm shift from deterministic, gene-focused approaches to stochastic, evolution-based frameworks represents more than a theoretical change—it offers practical pathways to more effective cancer treatments.

The transition from static, genetic-based treatment paradigms to dynamic, evolution-guided approaches represents a fundamental shift in cancer medicine that addresses the current crisis in the oncogene addiction paradigm. Our results contribute to this transition by providing quantitative evidence for evolutionary flexibility in tumor populations and demonstrating computational approaches for investigating these dynamics. As Chakravarty (2015) emphasizes, we must think kinetic rather than genetic, focusing on "a mechanism" among many rather than seeking "the mechanism."

Future clinical applications of these principles may ultimately lead to more effective, durable cancer treatments that account for tumor evolutionary potential rather than merely current genetic states. By learning from our success in driving species to extinction in other contexts, we

may develop more effective strategies for eliminating cancer populations through comprehensive understanding and targeting of their evolutionary capabilities.

Literature Cited

Chakravarty, A. (2015). An evolving view of cancer: Tumor heterogeneity and its implications. Presented at AACR Tumor Metastasis Conference, December 2, 2015.

Flavahan, W. A., Drier, Y., Liau, B. B., Gillespie, S. M., Venteicher, A. S., Stemmer-Rachamimov, A. O., ... & Bernstein, B. E. (2017). Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature, 529(7584), 110-114.

Gatenby, R. A., Silva, A. S., Gillies, R. J., & Frieden, B. R. (2009). Adaptive therapy. Cancer Research, 69(11), 4894-4903.

Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., ... & Swanton, C. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New England Journal of Medicine, 366(10), 883-892.

Gillies, R. J., Verduzco, D., & Gatenby, R. A. (2012). Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nature Reviews Cancer, 12(7), 487-493.

Greaves, M., & Maley, C. C. (2012). Clonal evolution in cancer. Nature, 481(7381), 306-313.

Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998). Genetic instabilities in human cancers. Nature, 396(6712), 643-649.

McGranahan, N., & Swanton, C. (2017). Clonal heterogeneity and tumor evolution: past, present, and the future. Cell, 168(4), 613-628.

Moran, P. A. P. (1958). Random processes in genetics. Mathematical Proceedings of the Cambridge Philosophical Society, 54(1), 60-71.

Pagliarini, R., Shao, W., & Sellers, W. R. (2015). Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Molecular Medicine, 7(3), 249-265.

Palm, M. M., Danen, E. H., & van Rheenen, J. (2018). Heritable tumor cell division rate heterogeneity induces clonal dominance. PLoS Computational Biology, 14(2), e1005954.

Shannon, C. E. (1948). A mathematical theory of communication. Bell System Technical Journal, 27(3), 379-423.

Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., ... & Settleman, J. (2007). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell, 131(1), 45-59.

Sottoriva, A., Kang, H., Ma, Z., Graham, T. A., Salomon, M. P., Zhao, J., ... & Curtis, C. (2015). A Big Bang model of human colorectal tumor growth. Nature Genetics, 47(3), 209-216.

Thompson, S. L., & Compton, D. A. (2008). Examining the link between chromosomal instability and aneuploidy in human cells. Journal of Cell Biology, 180(4), 665-672.

Weinstein, I. B., & Joe, A. (2008). Oncogene addiction. Cancer Research, 68(9), 3077-3080.